Scholarlink

Background <p>Monoclonal antibody (mAb) therapies are limited by factors affecting their pharmacokinetics (PK), such as anti-idiotypic antibodies (anti-ID Abs) and the antigen sink effect. To address this, we developed six pro-anti-TNFα Abs (pro-Infliximab) incorporating unique hinge regions (“Ab locks”) from different immunoglobulin subtypes linked via protease-sensitive peptides. The steric shielding formed by the endogenous hinge’s disulfide bonds provides a modular design that can be applied to various Ab drugs with minimal structural modification. Compared to other spatial hindrance strategies, this Ab lock approach is anticipated to offer a favorable immunogenicity profile.</p> Results <p>Among the variants, The IgG1 hinge exhibited the most robust masking capability among the evaluated domains, resulting in a 128-fold reduction in Infliximab’s antigen binding. IgG1 pro-Infliximab demonstrated low immunogenicity after repeated dosing and maintained stable PK in both naïve and immunized mice, retaining 74.2% serum levels one hour after TNFα challenge. It also reduced anti-ID Ab binding by 87.3-fold, while showing a trend toward decreasing Ab-mediated drug clearance in these treated mice.</p> Conclusions <p>This IgG1 Ab lock strategy provides binding-level proof of concept for several pro-Abs, offering the potential to mitigate immunogenicity. It blocked systemic hTNFα in an acute target challenge model and reduced clearance to preserve pro-Infliximab PK, ultimately helping to enhance patient quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Autologous hinge-masked anti-TNFα antibody to mitigate immunogenicity, antigen sink effects, and anti-idiotypic antibody interference

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月1日

查看全文
  • Bo-Cheng Huang,
  • Yun-Chi Lu,
  • Chih-Hung Chuang,
  • Shih-Ting Hong,
  • Kai-Wen Ho,
  • Yi-An Cheng,
  • Tzu-Yi Liao,
  • En-Shuo Liu,
  • Jun-min Liao,
  • Chiao-Yun Chen,
  • Tian-Lu Cheng,
  • I-Ju Chen,
  • Wen-Wei Lin

摘要

Background

Monoclonal antibody (mAb) therapies are limited by factors affecting their pharmacokinetics (PK), such as anti-idiotypic antibodies (anti-ID Abs) and the antigen sink effect. To address this, we developed six pro-anti-TNFα Abs (pro-Infliximab) incorporating unique hinge regions (“Ab locks”) from different immunoglobulin subtypes linked via protease-sensitive peptides. The steric shielding formed by the endogenous hinge’s disulfide bonds provides a modular design that can be applied to various Ab drugs with minimal structural modification. Compared to other spatial hindrance strategies, this Ab lock approach is anticipated to offer a favorable immunogenicity profile.

Results

Among the variants, The IgG1 hinge exhibited the most robust masking capability among the evaluated domains, resulting in a 128-fold reduction in Infliximab’s antigen binding. IgG1 pro-Infliximab demonstrated low immunogenicity after repeated dosing and maintained stable PK in both naïve and immunized mice, retaining 74.2% serum levels one hour after TNFα challenge. It also reduced anti-ID Ab binding by 87.3-fold, while showing a trend toward decreasing Ab-mediated drug clearance in these treated mice.

Conclusions

This IgG1 Ab lock strategy provides binding-level proof of concept for several pro-Abs, offering the potential to mitigate immunogenicity. It blocked systemic hTNFα in an acute target challenge model and reduced clearance to preserve pro-Infliximab PK, ultimately helping to enhance patient quality of life.